Okogen Acquires Ranpirnase Assets and Intellectual Property Portfolio
Okogen Acquires Ranpirnase Assets and Intellectual Property Portfolio Plano, Texas–(Newsfile Corp. – March 26, 2026) – Okogen Inc., a biotechnology company developing antiviral therapeutics, today announced the acquisition of the global intellectual property portfolio and development assets for ranpirnase from Orgenesis Inc. (OTC: ORGS), strengthening the company’s lead ophthalmic program and establishing a foundation for […]
Okogen Acquires Ranpirnase Assets and Intellectual Property Portfolio Read More »
Technology






